Table 2.
Distribution and intra-tissue combinations of MEN1 main tumours in our series of MEN1 patients
| Only PHPT n. (%) |
Only GEP-NET n. (%) |
Only pituitary adenoma n. (%) |
PHPT/GEP-NETs/Pituitary n. (%) |
PHPT/GEP-NETs n. (%) |
PHPT/pituitary adenomas n. (%) |
GEP-NETs/pituitary adenomas n. (%) |
PHPT not associated with classical MEN1 main tumours n. (%) |
Asymptomatic n. |
Total patients n. |
|---|---|---|---|---|---|---|---|---|---|
| 23 (15.86%) - 19 asymptomatic PHPT (13.10%) - 2 PHPT with osteoporosis (1.38%) - 1 PHPT with nephrocalcinosis - 1 PHPT with nephrocalcinosis and osteoporosis |
1 (0.69%) - 1 pNFTs |
2 (1.38%) - 2 PRLomas |
46 (31.72%) - 10 PHPT/gastrinoma/PRLoma (6.90%) - 8 PHPT/insulinoma/PRLoma (5.52%) - 1 PHPT/insulinoma/pituitary NFA 0.69%) - 14 PHPT/pNFTs/PRLoma (9.66%) - 4 pHPT/pNFTs/pituitary NFA (2.76%) - 2 PHPH/VIPoma/PRLoma (1.38%) - 1 PHPT/insulinoma/gastrinoma/corticotropinoma (0.69%) - 3 PHPT/gastrinoma/pNFTs/PRLoma (2.07%) - 2 PHPT/gastrinoma/pNFTs/pituitary NFA (1.38%) |
36 (24.83%) - 13 PHPT/gastrinoma (8.97%) - 12 PHPT/pNFTs (8.28%) - 4 PHPT/gastrinoma/pNFTs (2.76%) - 2 PHPT/gastrinoma/insulinoma (1.38%) - 1 PHPT/gastrinoma/glucagonoma (0.69%) |
24 (16.55%) - 17 PHPT/PRLoma (11.72%) - 5 PHPT/pituitary NFA (3.45%) - 1 PHPT/corticotropinoma (0.69%) - 1 PHPT/PRLoma/somatotropinoma (0.69%) |
3 (2.07%) - 3 gastrinoma/PRLoma (2.07%) |
10 (6.90%) - 3 PHPT with skin lesions (2.07%) - 4 PHPT with uterine myoma (2.76%) - 2 PHPT with adenoma of adrenal glands (1.38%) |
20 | 165 |
Footnotes: N. Number, PHPT Primary hyperparathyroidism, GEP-NETs Gastro-entero-pancreatic neuroendocrine tumours, pNFTs Pancreatic non-functioning tumours, PRLoma Prolactinoma, NFA Non-functioning adenoma, VIP Vasoactive intestinal peptide. Percentages were calculated with respect to MEN1 clinically affected patients (145)